Anti-Human Anthrax Toxin Receptor (Intermediate Domain) (ATR)
Roll over image to zoom in
Shipping Info:
For estimated delivery dates, please contact us at [email protected]
| Amount : | 0.1 mg |
| Content : | Concentration: 0.5 mg/ml Formulation: This polyclonal antibody is formulated in phosphate buffered saline (PBS) pH 7.4 containing 0.02% sodium azide as a preservative. |
| Storage condition : | This polyclonal antibody is stable for at least one week when stored at 2-8°C. For long term storage, aliquot in working volumes without diluting and store at –20°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. |
| Alternative Name : | TEM8 |
Specificity: Rabbit Anti-Human Anthrax Toxin Receptor (ATR) recognizes an epitope in the intermediate domain of Human, Mouse and Rat ATR. This polyclonal antibody was purified using affinity chromatography.
Background: The Anthrax toxin receptor (ATR) was initially discovered as the tumor endothelial marker 8 (TEM8). This protein, which exists in three isoforms (36, 40, and 60 kDa), is highly expressed in tumor vessels as well as in the vasculature of developing embryos, suggesting that it may normally play a role in angiogenesis. However, it also acts as the receptor for anthrax toxin. Following the binding of this protein by the protective antigen (PA) of anthrax, PA is cleaved and heptamerizes to form the binding site for both edema factor (EF) and lethal factor (LF). This complex is then endocytosed by the cell; acidification in endosomes allows the release of EF and LF into the cytoplasm where they interfere with MAPK signaling and induce apoptosis.
|
There are currently no product reviews
|
.png "ACE2/HEK293 Stable Cell Line")
